BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6889585)

  • 1. The serum levels of testosterone and prolactin in patients with prostatic carcinoma treated with various doses of Fostrolin and bromocriptin.
    Jeromin L
    Int Urol Nephrol; 1982; 14(1):51-6. PubMed ID: 6889585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of ergobromocriptine on serum testosterone and prolactin levels in patients with carcinoma of the prostate.
    Taşar C; Akdaş A; Kirkali Z
    Int Urol Nephrol; 1986; 18(1):71-4. PubMed ID: 2424860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testosterone metabolism in patients with advanced carcinoma of the prostate: a comparative in vivo study of the effects of oestrogen and antiprolactin.
    Jacobi GH; Sinterhauf K; Kurth KH; Altwein JE
    Urol Res; 1978; 6(3):159-65. PubMed ID: 758043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hormonal environment following treatment with a small dose of estrogen--small dose of estrogen alone and in combination with an anti-androgen].
    Hayashi T; Taki Y; Ikai K; Hiura M; Kiriyama T
    Hinyokika Kiyo; 1987 Jul; 33(7):1035-42. PubMed ID: 2446483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance of plasma testosterone and prolactin changes in advanced cancer of prostate treated with diethylstilbestrol or estramustine phosphate.
    Morales A; Nickel JC
    Urology; 1985 Nov; 26(5):477-81. PubMed ID: 3904134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of prolactin in modulating the effects of tamoxifen on growth of the Dunning R3327 rat prostate adenocarcinoma.
    Sylvester PW; Ip MM
    Prostate; 1987; 10(1):57-67. PubMed ID: 3822918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of prostatic carcinoma with phostrolin and bromocriptine while monitoring serum concentrations of testosterone and prolactin].
    Jeromin L
    Pol Tyg Lek; 1980 Mar; 35(10):359-62. PubMed ID: 7367321
    [No Abstract]   [Full Text] [Related]  

  • 8. Induced hypoprolactinemia and testicular steroidogenesis in man.
    Suescun MO; Scorticati C; Chiauzzi VA; Chemes HE; Rivarola MA; Calandra RS
    J Androl; 1985; 6(1):10-4. PubMed ID: 3972716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of prolactin and the anit-prolactin bromocriptin on the testosterone uptake and metabolism in androgen-sensitive and insensitive canine organs.
    Helmerich D; Altwein JE
    Urol Res; 1976 Nov; 4(3):101-5. PubMed ID: 1037036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Testosterone, FSH and LH level in the serum of patients with prostatic neoplasms, treated with female hormones].
    Weidner W; Krause W; Pust R; Engstfeld J; Rothauge CF
    Helv Chir Acta; 1978 Jul; 45(3):287-90. PubMed ID: 701064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of orchiectomy and various doses of stilbestrol on plasma testosterone levels in patients with carcinoma of the prostate.
    Mackler MA; Liberti JP; Smith MJ; Prout GR
    Surg Forum; 1970; 21():540-1. PubMed ID: 5535268
    [No Abstract]   [Full Text] [Related]  

  • 12. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
    Tsagarakis S; Tsiganou E; Tzavara I; Nikolou H; Thalassinos N
    Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of bromocriptine on prolactin secretion after dopaminergic receptor blockade with metoclopramide in patients with prostatic cancer treated with estrogens].
    Baranowska B; Szymanowski J; Jeske W
    Endokrynol Pol; 1984; 35(4):211-7. PubMed ID: 6510364
    [No Abstract]   [Full Text] [Related]  

  • 14. [Bromocriptine, a new therapeutic principle in prostatic adenoma and carcinoma. Basis, possibilities, limits].
    Jacobi GH; Altwein JE
    Dtsch Med Wochenschr; 1978 May; 103(19):827-33. PubMed ID: 77217
    [No Abstract]   [Full Text] [Related]  

  • 15. Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate.
    Maatman TJ; Gupta MK; Montie JE
    J Urol; 1985 Apr; 133(4):620-1. PubMed ID: 3981712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex hormone binding globulin binding capacity, testosterone, 5alpha-dihydrotestosterone, oestradiol and prolactin in plasma of patients with prostatic carcinoma under various types of hormonal treatment.
    Bartsch W; Horst HJ; Becker H; Nehse G
    Acta Endocrinol (Copenh); 1977 Jul; 85(3):650-64. PubMed ID: 325982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma testosterone in patients receiving diethylstilbestrol.
    Beck PH; McAnich JW; Goebel JL; Stutzman RE
    Urology; 1978 Feb; 11(2):157-60. PubMed ID: 628992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations of peripheral testosterone matabolism after induced hypoprolactinemia in patients with prostatic carcinoma.
    Jacobi GH; Altwein JE; Hohenfellner R
    Klin Wochenschr; 1979 Jan; 57(1):49-51. PubMed ID: 759717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma hormone levels in patients with prostatic carcinoma treated with diethylstilboestrol and estramustine.
    Bishop MC; Selby C; Taylor M
    Br J Urol; 1985 Oct; 57(5):542-7. PubMed ID: 3904908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients.
    Karr JP; Wajsman Z; Kirdani RY; Murphy GP; Sandberg AA
    J Urol; 1980 Aug; 124(2):232-6. PubMed ID: 7190620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.